Smith & Nephew PLC 6-K Filing

FAQ

Key Financial Figures

• $800 million — ected free cash flow upgraded to around $800 million ●   Further opportunities
• $200 million — io   identified, with an estimated $200 million non-cash   inventory provision in
• $1 billion — fficiencies. ●  More than $1 billion in free cash flow in 2028. ●&#
• $800 m — h flow. We now expect this to be around $800 million, driven by good working capital d
• $600 million — s was originally guided to be more than $600 million for 2025.   We expect post-tax
• $500 million — ble to reduce gross inventory by around $500 million. To achieve this significant and on-goi
• $200 million — hich we currently estimate to be around $200 million. Combined with the expansion and r
• $5.8 billion — ountries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent

Filing Documents

• a6170ksmithnephew.htm (6-K) — 54KB
• 0001654954-25-013739.txt ( ) — 55KB

business

business ●   2026 full year provisional guidance issued , building on 2025 progress   Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, will today present its new strategy, RISE, 2026 provisional guidance and 2028 financial targets at its Capital Markets Day in London.   The RISE strategy is designed to drive stronger returns for shareholders by elevating Smith+Nephew's financial and operational performance to new levels by raising the standard of care within our segments and reaching more patients with our continued focus on innovation.   This new strategy builds on the success of the 12-Point Plan, announced in 2022, through which we have transformed into a stronger, more agile, and higher growth company.   RISE has four elements:   ●   To  REACH  more patients by driving adoption of our differentiated portfolio and taking share across indications, settings and markets worldwide. ●   To  INNOVATE  to enhance the standard of care through accelerating   new product launches and rapidly scaling existing innovation platforms. ●   To  SCALE  through strategic investment, allocating capital to high return and high growth opportunities aligned to our portfolio priorities. ●   To  EXECUTE  efficiently, driving enterprise productivity and asset efficiency to expand our margins and returns.   Further details on the new strategy will be provided at the Capital Markets Day event in London later today.   Deepak Nath, Chief Executive Officer, commented:   "Smith+Nephew's new RISE strategy represents an ambitious but achievable new chapter. Our actions under the 12-Point Plan have created a fundamentally stronger business than three years ago and a springboard for future growth. RISE is our roadmap to reach more patients, deliver new categories of innovation, and further accele

Forward-looking Statements

Forward-looking Statements   This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks,

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at ww

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.           Smith & Nephew plc     (Registrant)             Date: December 08, 2025 By: /s/ Helen Barraclough     Helen Barraclough     Company Secretary

View Full Filing

View this 6-K filing on SEC EDGAR